Monkey pox vaccine: FDA approves change in how vaccine is delivered to extend supply

The vaccine can now be given to high-risk adults intradermally, meaning between the layers of skin, subcutaneously or under the skin, until now. This will allow providers to get up to five doses from a standard one-dose vial.

The new EUA allows subcutaneous vaccination for people under the age of 18 who are at high risk of infection.

“The continued spread of monkeypox virus in recent weeks has made it clear that our current vaccine supply will not meet current demand,” said FDA Commissioner Dr. Robert M. Khalif said. Report. “The FDA quickly explored other scientifically appropriate options to facilitate access to the vaccine for all affected individuals. By increasing the number of doses available, more individuals who wish to be vaccinated against monkeypox will now have the opportunity to do so.”

The move comes less than a week after the Biden administration declared monkeypox a public health emergency, giving the FDA and other government health agencies more flexibility to fight the spread of the virus.

Earlier on Tuesday, US Department of Health and Human Services Secretary Xavier Becerra issued a resolution paving the way for the FDA’s action.

“Last week, I declared monkeypox a public health emergency to help contain and end this outbreak and signal to the American people that we are taking our response to the next level,” Becerra said. Report. “Today’s action will allow the FDA to use additional authorities to increase the availability of vaccines to prevent monkeypox, while ensuring that vaccines meet high standards for safety, efficacy and manufacturing quality.”

As of Monday, the U.S. government had shipped 617,693 doses of Gino’s to states and jurisdictions. The U.S. Centers for Disease Control and Prevention estimates that at least 1.5 million people in the United States are eligible for the monkeypox vaccine.

As of Monday evening, CDC reports 8,934 probable or confirmed cases of monkeypox in 49 states, Puerto Rico, and the District of Columbia.

With intradermal vaccination, “Basically, you’re staying on the skin; you’re not going through the skin,” said Dr. Daniel Griffin, an infectious disease specialist at Columbia University.

Influenza and rabies vaccines have been administered by small-dose injection with intradermal injection, epidemiologist Dr. J Verma told CNN In an email.

“The skin contains specialized cells that help the vaccine stimulate the body’s immune system,” he wrote.

Griffin said these cells, called dendritic cells, can better develop the immune system.

“They live in the skin, and they’re great at teaching the immune system what to respond to,” he said.

“If you can give the monkeypox vaccine intradermally, you can give a smaller dose. … They need to demonstrate something that you get the same immune response,” he said.

CNN’s Jeremy Diamond, Brenda Goodman and Virginia Longmaid contributed to this report.

Leave a Reply

Your email address will not be published.